InnoCare Pharma Limited (HKG:9969)
12.56
+0.06 (0.48%)
Oct 21, 2026, 3:59 PM HKT
InnoCare Pharma Revenue
InnoCare Pharma had revenue of 608.43M CNY in the quarter ending June 30, 2026, with 73.75% growth. This brings the company's total for the last twelve months to 2.78B, up 110.46% year-over-year. In the year 2025, InnoCare Pharma had annual revenue of 2.37B with 135.27% growth. That makes InnoCare Pharma the 12,399th largest company in the world by revenue and 736th in Hong Kong.
Revenue (ttm)
2.78B CNY
Revenue Growth
+110.46%
P/S Ratio
8.23
Revenue / Employee
2.00M CNY
Employees
1,388
Market Cap
26.55B HKD
Revenue by Geography
- China 1.44B 60.6%
- Foreign 935.79M 39.4%
Fiscal year ended Dec 31, 2025 See the full InnoCare Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.37B | 1.37B | 135.27% |
| Dec 31, 2024 | 1.01B | 270.91M | 36.68% |
| Dec 31, 2023 | 738.54M | 113.13M | 18.09% |
| Dec 31, 2022 | 625.40M | -417.63M | -40.04% |
| Dec 31, 2021 | 1.04B | 1.04B | 76,368.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 20.63B |
| RemeGen | 9.24B |
| Shanghai Henlius Biotech | 8.58B |
| Zai Lab | 3.53B |
| Shanghai Junshi Biosciences | 3.49B |
| Everest Medicines | 2.78B |
| Biocytogen Pharmaceuticals (Beijing) | 1.96B |
| InSilico Medicine Cayman TopCo | 1.06B |
InnoCare Pharma News
- 8 days ago - InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China - GlobeNewsWire
- 27 days ago - China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion - Reuters
- 1 month ago - InnoCare Pharma Earnings Call Transcript: Q2 2026 - Transcripts
- 1 month ago - InnoCare Pharma Earnings release: Q2 2026 - Filings
- 1 month ago - InnoCare Pharma Slides: Q2 2026 - Filings
- 1 month ago - InnoCare Pharma Quarterly report: Q2 2026 - Filings
- 2 months ago - China's Innocare's psoriasis drug meets main goal in late-stage trial - Reuters
- 3 months ago - InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL - GlobeNewsWire